FilingsTodayDaesung Microbiological Labs.
At a glance
Daesung Microbiological Labs. filed 40 disclosures in the last 12 months, including 13 insider and 4 5% holder. The most recent key filing was on Jun 4.
Revenue for 2025 was ₩26B, up 9.2% on 2024. Operating margin was 2.7% against -6.5% a year earlier. Debt was 64% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩11.1B and operating loss of ₩988M.
The 2025 annual report lists 138 employees with an average tenure of 10.9 years and average pay of ₩44.7M, #1657 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩111.1M each on average. It paid ₩75 per common share in cash dividends, against ₩75 a year earlier (+0%). 이동규 and related parties held 38.60% at year end.
From the 2025 annual report
Staff: 138 (85 men, 53 women), of whom 10 on fixed-term contracts. Total pay for the year: ₩6.2B. Directors and auditors: 5, paid ₩555.5M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩75 | ₩75 | ₩75 |
| Payout ratio | 47.6% | -16.1% | -41.9% |
| Yield (as filed) | 1.02% | 0.82% | 0.67% |
| Total cash dividends | ₩285M | ₩285M | ₩285M |
Largest shareholder
이동규 holds 32.02%; with 1 related party the group holds 38.60% of common shares at year end.
Auditor: 한울회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.